Rx Product Updates (February 2016)

Contemporary ClinicFebruary 2016
Volume 2
Issue 1

Read about the new Rx products featured in February 2016.


Indication:The FDA recently approved Actavis’ Viberzi, a twice-daily, oral treatment for irritable bowel syndrome with diarrhea. The drug will be available in 75-mg and 100-mg dosage strengths. The recommended dosage in adults is 100 mg twice daily with food, but patients who do not have a gallbladder, cannot tolerate the 100-mg dose, are receiveing concomitant OATP1B1 inhibitors, or have mild or moderate hepatic impairment should take 75 mg twice daily with food.

Dosage Form:Tablets: 75 mg and 100 mg

For More Information:actavis.com

DAKLINZAMarketed by:Bristol-Myers Squibb Company

Indication:The FDA approved Bristol-Myers Squibb’s Daklinza to treat chronic hepatitis C (HCV) genotype 3. The product is indicated for use with sofosbuvir, and it is the first time patients with HCV genotype 3 have a 12-week, once-daily, all-oral treatment option. Daklinza comes in 60- mg and 30-mg dosage strengths.

Dosage Form:Tablets: 60 mg and 30 mg

For More Information:bms.com

XIFAXANMarketed by:Salix Pharmaceuticals, Inc

Indication:The FDA approved Salix’s Xifaxan as a treatment for adults with irritable bowel syndrome with diarrhea. The product comes in a 550-mg dosage strength, and a full course is available in a 2-week pack of 42 pills.

Dosage Form:Tablets: 550 mg

For More Information:valeant.com

Related Content
© 2024 MJH Life Sciences

All rights reserved.